Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Merrill Upgrades King Pharmaceuticals to 'Buy'

Merrill Lynch upgraded King Pharmaceuticals (KG) to buy from neutral.

On Thursday the company returned to profit. It posted 32 cents fourth-quarter earnings per share (excluding special items), and CEO Jefferson Gregory announced his plan to retire. Analyst Gregory Gilbert say he sees multiple expansion in 2004.

Gilbert notes the potential progress with the Securities and Exchange Commission, which has been investigating the drug maker's marketing and pricing practices. He says King has taken the right steps to better manage and communicate its inventory situation, which had concerned investors.

Gilbert expects new management to focus more on R&D, which is needed. He believes investors will give new management the benefit of the doubt when it comes to assessing the risks facing the company. Gilbert sees $1.45 2004 earnings per share, and $1.68 2005 (GAAP). He has a $25 target.

blog comments powered by Disqus